IPS Therapeutique Inc.
Bespoke non-clinical drug development services
The most predictive models of human disease to address the translational challenges of the pharmaceutical industry
Metabolic Heart Failure: From Mitochondria to Systemic Dysfunction
Would you like to learn more about metabolic heart failure? In this video, we highlight the features that distinguish it from other forms of heart failure.
Metabolic heart failure begins in the mitochondria, where energy deficit and oxidative stress disrupt normal cellular function. Over time, these functional disturbances trigger structural remodeling, including fibrosis and hypertrophy, that further weaken and stiffen the ventricle.
Click ‘Learn More’ to watch the full video.
Accelerate Sepsis Drug Discovery
September is Sepsis Awareness Month, and at IPS Therapeutique we remain dedicated to advancing research in this critical field. We are proud to introduce our rodent model, adapted from our previous publication, to accelerate the discovery of novel therapies for sepsis—a life-threatening condition driven by the body’s overwhelming response to infection.
Are you or your team developing innovative therapies for sepsis? Let’s connect and explore how our preclinical models can help translate your ideas into clinical impact.
Angiogenesis May Compensate Vessel Occlusion to Mitigate CTEPH Severity
Presented at ATS 2025, this talk showcased how micro-CT imaging reveals angiogenesis inhibition in our microsphere + Sugen-induced CTEPH rat model—a novel preclinical model designed to advance research in type IV pulmonary hypertension (CTEPH).
The model offers a powerful platform to accelerate the development of new therapeutic approaches targeting this complex pathology. The presentation highlights the hemodynamics and remodeling associated with CTEPH.
Meet Our Teams
Team Heart Failure:
William’s team induces heart failure (HF)by various surgical and pharmacological methods: coronary ligation (MI), trans-aortic constriction (TAC), aorto-caval shunt (ACS), etc. Two-hit (2-hit) models creating HF with preserved or reduced ejection fraction (HFpEF or HFrEF) are used routinely to reproduce human HF progression.
The team combines invasive hemodynamics with imaging and telemetry to measure all aspects of cardiac function and remodeling in mice, rats, rabbits.
Team R&D:
This is where most projects start: New models are designed in collaboration with YOUR team, and Emilie’s team turns them into sensitive, reproducible, and translatable Discovery tools.
Under Emilie’s direction, unique models of pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), preeclampsia, hemorrhagic shock, heart failure due to volume overload, as well as countless others have been validated, published, and have since joined the mainstream in preclinical drug research.
Team Safety:
Refka and Helene lead Team Safety with tolerability assays ensuring the integrity of cardiac, vascular, respiratory, and CNS function. In addition, the team regularly monitors renal and hepatic function.
Safety assessment uses healthy animals: while disease induction is not an issue, exotic routes of administration –such as stereotaxic intracerebroventricular injection (ICV) are commonplace for Refka and Helene’s team. They work closely with IPST’s Quality Assurance Unit to ensure the GLP-compliance of their studies, fit for regulatory filing.
Team Inflammation:
The Inflammatory Diseases Team handles the fastest growing group of indications at IPST. Whether the induction is chemical or surgical, or immune-triggered, Rachel and Maxime’s teams test models of pulmonary, renal, hepatic fibrosis, sclerosis, and auto-immune diseases.
Their models combine functional assessment with biomarkers quantification and histological analysis to maximize the predictive power of the tests.
Respiratory Diseases Team:
Under the leadership of Sandra Gagnon, the team handles disease induction and symptoms monitoring using non-invasive plethysmography and forced oscillometry, as well as telemetry implants for respiratory function.
Sandra and Camille bring expertise in small-animal inhalation and nebulization, and routinely administer dry powders and liquids as therapies over weeks and months.
Team Safety:
Refka and Helene lead Team Safety with tolerability assays ensuring the integrity of cardiac, vascular, respiratory, and CNS function. In addition, the team regularly monitors renal and hepatic function.
Safety assessment uses healthy animals: while disease induction is not an issue, exotic routes of administration –such as stereotaxic intracerebroventricular injection (ICV) are commonplace for Refka and Helene’s team. They work closely with IPST’s Quality Assurance Unit to ensure the GLP-compliance of their studies, fit for regulatory filing.
Team Inflammation:
The Inflammatory Diseases Team handles the fastest growing group of indications at IPST. Whether the induction is chemical or surgical, or immune-triggered, Rachel and Maxime’s teams test models of pulmonary, renal, hepatic fibrosis, sclerosis, and auto-immune diseases.
Their models combine functional assessment with biomarkers quantification and histological analysis to maximize the predictive power of the tests.
IPS Therapeutique
IPS Therapeutique (IPST) is a Contract Research Organization dedicated to the preclinical evaluation of the efficacy and safety new drugs using the most advanced in vitro and in vivo models of diseases.
25+ Years of Experience
Established in 1999, we have conducted more than 3,000 preclinical cardiac safety and efficacy studies and over 120 GLP-compliant studies in support of FDA, EMEA, Health Canada and MoHW regulatory filings.
A Team Built Just Like Yours
At IPST, our senior management team is fully engaged on every project.
We invite our clients to talk through challenges, business requirements and quantitative expectations for each project. Our team understands the linkages between tasks, projects costs and schedules.
Equipped for success
IPS Therapeutique (IPST) has a 33,000 square-foot state-of-the-art purpose-designed laboratory and office complex located in Sherbrooke, Quebec – in close proximity to Montréal, Québec, Burlington and Boston.
When It Doesn't Exist, We Make It
A dedicated R&D team is constantly developing new models to assist in the nonclinical development of your next blockbuster.
20+ models get validated every year, and join our unique toolbox for efficacy testing.
IPS Therapeutique
IPS Therapeutique (IPST) is a Contract Research Organization dedicated to the preclinical evaluation of the efficacy and safety new drugs using the most advanced in vitro and in vivo models of diseases.
25+ Years of Experience
Established in 1999, we have conducted more than 3,000 preclinical cardiac safety and efficacy studies and over 120 GLP-compliant studies in support of FDA, EMEA, Health Canada and MoHW regulatory filings.
At IPST, our senior management team is fully engaged on every project. We invite our clients to talk through challenges, business requirements and quantitative expectations for each project. Our team understands the linkages between tasks, projects costs and schedules.
A Team Built Just Like Yours
IPS Therapeutique (IPST) has a 33,000 square-foot state-of-the-art purpose-designed laboratory and office complex located in Sherbrooke, Quebec – in close proximity to Montréal, Québec, Burlington and Boston.
Equipped for success
When It Doesn't Exist, We Make It
A dedicated R&D team is constantly developing new models to assist in the nonclinical development of your next blockbuster. 20+ models get validated every year, and join our unique toolbox for efficacy testing.